We transform the most promising oncology innovations into highly competitive opportunities that benefit patients, researchers, investors, and Ontario's economy. Cancer Breakthroughs. Realized.
The pitch competition showcases six Ontario-based entrepreneurial researchers working in the oncology space to pitch their innovative research ideas to a panel of judges.
The 6th annual Falcons’ Fortunes competition will be held in Toronto on Thursday, April 4, 2019.
FACIT Features: Portfolio company Fusion Pharma launches Phase 1 trial for next-gen radiotherapeutic
FACIT congratulates portfolio company Fusion Pharma on significant clinical development milestone.
Fusion Pharma announced the first patient dosing with lead candidate in Phase 1 trial for solid tumors.
"For innovation, open science means open for business", February 6, 2019
"U.S. biotech giant Celgene invests in Ontario-developed blood-cancer drug in potential $1-billion deal", January 29, 2019
FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy
Largest transaction to date for Canadian-discovered preclinical asset arises from Ontario collaborators
Triphase Accelerator, together with its majority shareholder FACIT, today announced a new strategic collaboration with Celgene for a first-in-class preclinical therapeutic targeting the WDR5 protein for the treatment of blood cancers including leukemia.
Capital leverages Ontario’s strengths in genomics and informatics, deepens FACIT’s tech portfolio
FACIT's Compass Rose Oncology Fund is providing the follow-on investment. DNAstack also previously received capital from FACIT's early-stage Prospects Oncology Fund, illustrating FACIT's strategy to ensure promising companies grow roots and scale up in Ontario.